Finanzen von BioCardia Inc (BCDA)BCDABioCardia Inc

BioCardia Inc (BCDA) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Reconstructive Division, accounting for 92.7% of total sales, equivalent to $521.00K. Another important revenue stream is Spine Division. Understanding this composition is critical for investors evaluating how BCDA navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, BioCardia Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -1803.19%, provide a clear picture of how effectively BCDA converts its operational activities into shareholder value.

In the context of the broader market, BCDA competes directly with industry leaders such as NCEL and BIVI. With a market capitalization of $17.26M, it holds a significant position in the sector. When comparing efficiency, BCDA's gross margin of N/A stands against NCEL's N/A and BIVI's N/A. Such benchmarking helps identify whether BioCardia Inc is trading at a premium or discount relative to its financial performance.

BioCardia has shown a significant improvement in its cash position, increasing from $2.5 million to $4.1 million, which supports its R&D efforts. However, it has recorded consistent net losses, with the latest being -$3.9 million for the first half of 2026.